Karlsruhe / 26 June 2024 – The medavis Group (“medavis” or “Group”) has signed an agreement to acquire medDream. This strategic collaboration enhances the Group’s portfolio with a universal medical zero-footprint viewer and marks an important milestone for the internationalization of the Group.
The acquisition of medDream is a strategic step to strengthen the Group’s portfolio and further expand into international markets. The innovative medDream viewer plays a key role in this strategy. It can be universally used as a high-performance enterprise viewer in various medical specialties. At the same time, it will become a key component of the medavis referral and patient portal, thus supporting the entire patient pathway.
“The acquisition of the medDream portfolio ideally supports our group strategy to significantly expand our international activities over the next few years. We share the conviction of medDream that the world is in strong need for a universal medical viewer,” says Juergen Roth, Chief Revenue Officer of the medavis Group. “This is where medDream fits in perfectly”.
“We are proud of this strategic collaboration, marking a significant milestone in enhancing the value delivered to worldwide healthcare”, explain medDream co-founders Tomas Dumbliauskas and Vytautas Baublys. “The resulting synergies with medavis will accelerate product development, expand cloud support, and increase value for existing medDream customers, OEM vendors, and distributors. The medDream team is excited about the new horizons this partnership opens, and we are confident that together with medavis, we will achieve greater success in providing universal access to medical imaging and intelligence”.
Thomas Simon, CEO of the medavis Group, is convinced: “Due to the experienced team in Kaunas, Lithuania and the innovative product strategy, medDream is excellently positioned in the international OEM business and already works with more than 400 partners worldwide, with a big potential to grow.”
The medDream Viewer is certified as a Class IIB medical device in accordance with the European Medical Device Regulation (MDR) and is FDA cleared for diagnostic use. Certifications for other countries underline the high quality and safety standards.
